| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 07/28/2005 | WO2005049211A3 Fiber rich fraction of trigonella foenum-graceum seeds and its use as a pharmaceutical excipient |
| 07/28/2005 | WO2005049089A3 Use of perfluoropolyethers phosphates as stabilizing agents for polyphenols in cosmetic and/or dermatological compositions |
| 07/28/2005 | WO2005040382A3 Cherkasky fusion proteins containing antibody-, antigen- and microtubule-binding regions and immune response-triggering regions |
| 07/28/2005 | WO2005035727A3 Polymer derivatives |
| 07/28/2005 | WO2005027828A3 Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof |
| 07/28/2005 | WO2005025512A3 Cobalamin conjugates for anti-tumor therapy |
| 07/28/2005 | WO2005011647A3 Pharmaceutical composition |
| 07/28/2005 | WO2005002627A3 Conjugated complement cascade inhibitors |
| 07/28/2005 | WO2005000360A3 Peg derivatives having an amidocarbonate linkage |
| 07/28/2005 | WO2004080284A9 Antibody-targeted photodynamic therapy |
| 07/28/2005 | WO2004066938A3 Method and composition for lowering cholesterol |
| 07/28/2005 | WO2004043363A8 Protein-stabilized liposomal formulations of pharmaceutical agents |
| 07/28/2005 | WO2004033620A3 Methods and compositions for therapeutic use of rna interference |
| 07/28/2005 | US20050165476 Can serve as a carrier for a very broad range of drugs, possibly including every drug presently used, being considered for use, or likely to be used in the future to inhibit stenosis |
| 07/28/2005 | US20050165245 Transferring drugs; antitumor agents, anticancer agents |
| 07/28/2005 | US20050165227 Antiproliferative agents; gene overexpression |
| 07/28/2005 | US20050165188 Water-soluble or water-swellable crosslinked copolymers |
| 07/28/2005 | US20050165102 Improved bioavailability by complexing a drug such as metformin with an ionic moiety such as a fatty acid; e.g. metformin laurate; wrong claims attached to this publication |
| 07/28/2005 | US20050165100 Conjugated fatty acid esters |
| 07/28/2005 | US20050165094 Chemical compounds containing a superoxide scavenger and an organic nitrate or nitrite moiety |
| 07/28/2005 | US20050165091 includes a buffering agent to stabilize and maintain the pH below 9 in an aqueous dispersion; slow the degradation; shelf-life |
| 07/28/2005 | US20050165038 Analgetic dosage forms that are resistant to parenteral and inhalation dosing and have reduced side effects |
| 07/28/2005 | US20050164997 a 3-oxo-androstancarbothioic acid compound; respiaratory system disorder |
| 07/28/2005 | US20050164994 Using a drug delivery device containing radiation seeds at predetermined positions and a codrug that has two drug moieties covalently linked, preferably a coitcosteroid linked to a second corticosteroid, an antiproliferative agent, or a non-steroidal antiinflammatory agent; radiotherapy; prostate cancer |
| 07/28/2005 | US20050164986 Especially the sulfobutyl ether cyclodextrin, Captisol"; simplified aqueous formulations without conventional preservatives; nontoxic; storage stability and freeze resistance; biostatic and biocidal towards E coli, Pseudomonas aeruginzosa, Stapphylococcus aureus, Candida albicans, and Aspergillus niger |
| 07/28/2005 | US20050164984 Chondroitin synthase gene and methods of making and using same |
| 07/28/2005 | US20050164972 Cationic lipids capable of facilitating transport of biologically active agents or substances into cells; lipid aggregate macromolecular complex interacts with cells making the polyanionic macromolecule available for absorption and uptake by the cell |
| 07/28/2005 | US20050164971 Acyclic and macrocyclic, aliphatic diammonium surfactants for use in forming lipid aggregates for drug delivery of macromolecules; improved versatility among different cell types and broadened range of molecules to be carried |
| 07/28/2005 | US20050164968 RNA interference mediated inhibition of ADAM33 gene expression using short interfering nucleic acid (siNA) |
| 07/28/2005 | US20050164967 RNA interference mediated inhibition of platelet-derived endothelial cell growth factor (ECGF1) gene expression using short interfering nucleic acid (siNA) |
| 07/28/2005 | US20050164966 Aging, cancer, autoimmune diseases, inflammatory/allergic diseases |
| 07/28/2005 | US20050164964 Mixture of a nucleic acid and a chitosan with branching groups attached to the amino group, selected from alkyl groups with 2 or more carbon atoms, monosaccharides, oligosaccharides or polysaccharides; gene therapy, genetic vaccines, antisense therapy, anticarcinogenic agents, autoimmune diseases |
| 07/28/2005 | US20050164933 Method of reducing injury to mammalian cells |
| 07/28/2005 | US20050164927 Aqueous sustained-release formulations of proteins |
| 07/28/2005 | US20050164919 Bactericides; peptide antibiotics |
| 07/28/2005 | US20050164916 Glycopeptide phosphonate derivatives |
| 07/28/2005 | US20050164915 Compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin |
| 07/28/2005 | US20050164910 Decomposing gelatin or collagen using collegenase; purification by gel filtration; antiallergens |
| 07/28/2005 | US20050164391 Cationic lipids capable of facilitating transport of biologically active agents or substances into cells; lipid aggregate macromolecular complex interacts with cells making the polyanionic macromolecule available for absorption and uptake by the cell |
| 07/28/2005 | US20050164292 Efficient synthesis of protein-oligonucleotide conjugates |
| 07/28/2005 | US20050164267 Using caudal-1 gene (CDX-1) as diagnostic indicator of stomach or esophageal cancer; immunodiagnostics |
| 07/28/2005 | US20050164224 Cancers such as lymphomas, carcinoma, ovarian cancer, melanoma, colorectal cancer, prostate cancer, lung cancer, bladder cancer |
| 07/28/2005 | US20050163914 coating prosthetics by gas phase polymerization a dimer of 4-amino-[2,2]-paracyclophane, then immersion in water containing drugs, to form drug delivery devices having uniform drug release |
| 07/28/2005 | US20050163868 mixtures of plant extracts, cellulose esters, sodium bicarbonate and silica, having improved disintegration and dissolution properties |
| 07/28/2005 | US20050163859 Injectable compositions for the controlled delivery of pharmacologically active compound |
| 07/28/2005 | US20050163856 Abuse-resistant sustained-release opioid formulation |
| 07/28/2005 | US20050163853 Novel biomaterials their preparation and use |
| 07/28/2005 | US20050163850 Administration of levodopa and carbidopa |
| 07/28/2005 | US20050163849 Compositions and dosage forms for enhanced absorption of iron |
| 07/28/2005 | US20050163848 complexed with transport moiety comprising a lauryl sulfate salt; complex provides an enhanced absorption of the drug in the lower gastrointestinal tract; to control seizures or neuropathic pain with once daily administration |
| 07/28/2005 | US20050163846 Preparation composition containing acid-unstable physiologically active compound, and process for producing same |
| 07/28/2005 | US20050163841 to controllably deliver orally a drug at a substantially zero order delivery rate a during a window; improved oral absorption |
| 07/28/2005 | US20050163835 Gefitinib or salt with and a water-soluble cellulose ether or an ester of a water-soluble cellulose ether; increased absorption and/or bioavailability and may reduce inter-patient variability; prevents precipitation in higher pH upper GI |
| 07/28/2005 | US20050163833 gelatin-free soft capsules containing active ingredients; reduced glyceamic index; Significant improvements, especially with regard to brittleness, storage stability in changing conditions and sorption behavior |
| 07/28/2005 | US20050163832 liposome, safe and efficient delivery of agents, i.e. proteins, nucleic acids, small molecules and/or other drugs, into cell of higher organism in vitro or in vivo; transducing polypeptide-lipid vesicle complex; protein transduction domain of HIV-1 TAT protein, VP22 herpes virus or Antennapedia protein |
| 07/28/2005 | US20050163830 matrix-forming polymer comprises at least one active substance and at least one gas-forming component; comprises at least one carbon dioxide-forming substance reducing or suppressing the unpleasant taste of the active substance |
| 07/28/2005 | US20050163803 Non-animal origin stabilizers and processes for producing the same |
| 07/28/2005 | US20050163788 Prevention and treatment of amyloidogenic disease |
| 07/28/2005 | US20050163787 Immunological adjuvant |
| 07/28/2005 | US20050163786 Compounds and methods for modulating adhesion molecule function |
| 07/28/2005 | US20050163776 Treatment of tse infection |
| 07/28/2005 | US20050163774 conjugate of an antibody exhibiting binding specificity for an extracellular epitope of c-erB-2 protein and a plant derived toxin effective against neoplastic cells consisting of gelonin, full length recombinant gelonin, functional gelonin fragments and functional gelonin derivatives |
| 07/28/2005 | US20050163752 Human interferon-beta formulations |
| 07/28/2005 | US20050163750 Methods of preventing aggregation of various substances upon rehydration or thawing and compositions obtained thereby |
| 07/28/2005 | US20050163745 Immunogens; polyesters; glycolic acid-lactic acid copolymers; vaccines; delayed release; mucosal/parenteral administration |
| 07/28/2005 | US20050163743 Composition of polymers |
| 07/28/2005 | US20050163728 A mixture of polypeptides, as calcium binding protein for reducing bone loss and reducing renal phosphate excretion; biodrug for treating bone disorders; injectable solution or dispersed in toothpaste or a mouthwash or gum patch |
| 07/28/2005 | US20050163724 Contains steroidal anti-inflammatory drug, carrier (saccharides, sugar alcohols, amino acids), and water |
| 07/28/2005 | US20050163722 Optimised formulation of tobramycin for aerosolization |
| 07/28/2005 | US20050163720 May be used to prepare novel aerosol formulations, and can be advantageous in terms of improving the stability of the aerosol formulation, reducing drug deposition, increasing shelf life |
| 07/28/2005 | US20050163718 Denatonium benzoate, and cardiotoxic compounds, quinacrine, chloroquine, gamma hydroxybutramide, lidocaine; anesthetic is propofol; prevent accidental death |
| 07/28/2005 | US20050163716 Methods of preparing gaseous precursor-filled microspheres |
| 07/28/2005 | US20050163708 Chimeric antibody with specificity to human B cell surface antigen |
| 07/28/2005 | DE10361599A1 Flüssigformulierung von Antikörperkonjugaten Liquid formulation of antibody conjugates |
| 07/28/2005 | DE10361598A1 The freeze-dried pharmaceutical composition as the conjugate of an antibody with a mytansinoid, for the treatment of cancers, is set to a given concentration and pH value before freeze drying |
| 07/28/2005 | DE10361022A1 Topische Zubereitungen enthaltend Dimethylsulfoxid und Dexpanthenol Topical preparations containing dimethyl sulfoxide and panthenol |
| 07/28/2005 | DE10360847A1 Medical lubricant gel, useful in ear, nose and throat medicine, urology and gynecology, comprising gel former, care component and antimicrobial |
| 07/28/2005 | DE10043321B4 Verwendung eines transdermalen therapeutischen Systems zur Behandlung der Parkinsonschen Krankheit, zur Behandlung und Prävention des prämenstruellen Syndroms und zur Lactationshemmung Use of a transdermal therapeutic system for the treatment of Parkinson's disease, for the treatment and prevention of premenstrual syndrome and Lactationshemmung |
| 07/28/2005 | CA2593353A1 Drug delivery system |
| 07/28/2005 | CA2553594A1 Particle-induced ghrelin immune response |
| 07/28/2005 | CA2553325A1 Chaperonin 10 modulation of toll-like receptor-inducible cytokine and chemokine secretion |
| 07/28/2005 | CA2552916A1 Metal complexes having vitamin b12 as a ligand |
| 07/28/2005 | CA2552887A1 Transdermal delivery device for dihydropyridine type calcium antagonists containing at least one fatty acid |
| 07/28/2005 | CA2552677A1 Controlled release cgrp delivery composition for cardiovascular and renal indications |
| 07/28/2005 | CA2552521A1 Compositions comprosing memantine and polyanionic polymers for administration to the eye |
| 07/28/2005 | CA2552484A1 Confection product containing urea |
| 07/28/2005 | CA2551121A1 Crosslinked hyaluronic acid compositions for tissue augmentation |
| 07/28/2005 | CA2549524A1 Encapsulation of chemical compounds in fluorous-core and fluorous-inner-shell micelles formed from semifluorinated-block or fluorinated-block copolymers |
| 07/27/2005 | EP1557472A1 Sodium chondroitin sulfate, chondroitin sulfate-containing material and processes for producing the same |
| 07/27/2005 | EP1557463A1 Improved methods for processing activated protein C |
| 07/27/2005 | EP1557179A1 Analgesic dosage forms that are unable to be inhaled or injected |
| 07/27/2005 | EP1557170A2 Cellulose sulfate and other sulfated polysaccharides to prevent and treat papilloma virus infection and other infections |
| 07/27/2005 | EP1557167A1 Viral inhibition by long-chain alcohols alkanes fatty acids and amides |
| 07/27/2005 | EP1557164A1 Adhesive patch containing tulobuterol |
| 07/27/2005 | EP1557146A1 Heat generating article |
| 07/27/2005 | EP1556090A1 Polymer compositions for administration to animals |
| 07/27/2005 | EP1556087A2 Liquid conjugates of solid pharmaceuticals |
| 07/27/2005 | EP1556086A2 Solid and semi-solid polymeric ionic conjugates |
| 07/27/2005 | EP1556085A2 Compounds for the treatment of metabolic disorders |
| 07/27/2005 | EP1556084A2 Methods of regulating body weight |